Skip to main content

Advertisement

Table 1 Representation of the cases for diagnosis and PET/CT intensity values

From: Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease

CaseFinal diagnosisLocationBiopsyPainRAPDProptosis (Hertel in mm)BCVAPET SUVmax lesionPET SUVmax bone marrowPET SUV max LN level 2
1IOIApex with posterior extensionModerateNoYes (24–20)0.61.04 (moderate)2.0711.36
2IOIMyositis+SevereNoYesa1.00.68 (low)2.017.97
3IOILacrimal gland+ModerateNoNo1.23.88 (high)5.3211.32
4TEDPan-myositisNoneNoYes (23–23)1.00.33 (low)2.915.45
5IgG4+Myositis+MildNoYes (16–24)1.21.58 (moderate)4.438.90
6IOIDiffuse mass+ModerateNoYesa0.93.11 (high)3.7315.87
7IOIDiffuse mass+ModerateNoYesa1.02.12 (high)3.2714.45
8MeningiomaApexNoneYesNo0.60.79 (low)2.495.81
9IOIDiffuse mass+SevereYesNo0.53.82 (high)3.6412.12
10TEDPan-myositisMildNoYes (29–29)0.73.47 (high)4.0712.10
11IOIMyositis+SevereNoNo0.94.24 (high)3.5213.71
12IOIMyositis+SevereNoNo1.00.68 (low)4.8319.15
  1. IOI = idiopathic orbital inflammation; TED = thyroid eye disease; RAPD = relative afferent pupillary defect; BCVA = best-corrected visual acuity
  2. aClinical and radiological proptosis, not quantified with Hertel